Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare
FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq:CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications. A copy of BioCellgraft’s announcement of the agreement can be accessed here: https://www.prweb.com/releases/biocellgraft-finalizes-commercialization-agreement-with-celularity-for-the-manufacture-and-distribution-of-products-for-therapeutic-use-in-oral-healthcare-302025082.html.
Related news for (CELU)
- Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
- 24/7 Market News Snapshot 14 October, 2025 – Celularity Inc. Class A Common Stock (NASDAQ:CELU)
- MoBot’s Stock Market Highlights – 07/15/25 06:00 AM
- Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
- Celularity Receives Nasdaq Notice Regarding Form 10-Q